Impact of post-thoracotomy analgesia with dexmedetomidine and morphine on immunocytes: a randomized clinical trial

Pengfei Lei, Jin Wang, Shan Gao, Bo Du, Hao Wang, Weichun Li, Fei Shi, Aijun Shan

Abstract
Objective: This study aimed to investigate the impact of post-thoracotomy analgesia with dexmedetomidine and morphine on immunocytes.
Methods: A total of 118 patients with post-thoracotomy Patient-Controlled Intravenous Analgesia (PCIA) in our hospital from March 2016 to July 2018 were randomly selected and divided into the Composite (COM) Group (57 patients administered with dexmedetomidine [1.0 μg.kg⁻¹ body weight] and morphine [0.48 mg.kg⁻¹ body weight]) and the Morphine (MOR) group (61 patients administered with morphine [0.48 mg.kg⁻¹]). The values of lymphocyte subsets (CD3+, CD4+, and CD8+) and Natural Killer cells in the peripheral blood of these two groups were detected by FACSCalibur flow cytometry at different time points (before anesthesia induction [T0], immediately after tracheal extubation [T1], 12 hours after surgery [T2], 24 hours after surgery [T3], 48 hours after surgery [T4], 72 hours after surgery [T5], and 7 days after surgery [T6]). The doses of morphine at T3 to T5 and the adverse reactions between the two groups were also recorded and compared.
Results: The CD3+ level and the CD4+/CD8+ ratio at T2 to T5 and the CD4+ level and NK cells at T3 to T5 were significantly higher in the COM Group than in the MOR Group (p < 0.05). The postoperative morphine dose and the incidence of postoperative itching, nausea, and vomiting were significantly lower in the COM Group than in the MOR Group (p < 0.05).
Conclusions: Dexmedetomidine combined with morphine for post-thoracotomy PCIA can improve the function of immunocytes, reduce morphine consumption, and reduce the adverse reactions during analgesia induction.

Received 28 May 2019; accepted 9 December 2019
Available online 11 May 2020

KEYWORDS
Thoracotomy; Dexmedetomidine; Morphine; Analgesia; Immunocytes

© 2020 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author.
E-mails: cnpengfellei@163.com (F. Shi), abv236@126.com (A. Shan).

https://doi.org/10.1016/j.bjane.2020.04.017
© 2020 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Patients undergoing thoracotomy frequently experience severe pain after surgery, which leads to the inhibition of immune function, specifically cellular immunity, resulting in a bad prognosis. Clinically, to alleviate severe pain after thoracotomy, opioid analgesics, such as morphine, are often used for their analgesic effects. However, evidence based on some experimental studies suggests that morphine may inhibit the cellular immunity of the body, thereby possibly promoting the growth and metastasis of residual tumor cells.

As a specific α2-adrenergic receptor agonist, dexmedetomidine can effectively reduce the early body stress and inflammatory response in patients after surgery and alleviate the immunosuppressive effects caused by opioids. Studies have shown that dexmedetomidine combined with morphine for non-thoracic surgery can effectively reduce morphine consumption by 20%-30%.

This study attempted to use dexmedetomidine-morphine Patient-Controlled Intravenous Analgesia (PCIA) as post-operative analgesia in patients after thoracotomy, aiming to investigate its impact on postoperative immune function.

Methods

General information

This was a randomized clinical study conducted in Shenzhen People’s Hospital from March 2016 to July 2018. It was approved by the hospital’s ethics committee. All the patients and their families provided the informed consent.

Patients with the following characteristics were included in the study: 1) Patients with intrathoracic tumors requiring thoracotomy, 2) Patients with the American Society of Anesthesiologists physical status score of I or II, 3) Patients aged between 18 and 80 years, and 4) Patients who were not treated with radiotherapy or chemotherapy 14 days before surgery. However, patients with the following characteristics were excluded: 1) Patients experiencing major bleeding after surgery, 2) Patients requiring a large amount of allogeneic blood infusion, 3) Patients experiencing allergic reactions, and 4) Patients with serious organ dysfunction, serious infection, or history of immune system diseases and endocrine system diseases.

All the patients were randomized into the following groups: the composite (COM) Group (dexmedetomi-
dine + morphine) and the morphine (MOR) Group (only morphine) using a random number table.

Method of anesthesia

The two groups were restricted from eating, drinking, and taking medicines 8 hours before surgery. After each patient was sent into the surgery room, the venous access was established for the routine monitoring of the patient’s blood pressure, heart rate, electrocardiogram, and arterial blood gas.

Regarding anesthesia induction, 0.05 mg.kg⁻¹ midazolam (Roche, Shanghai, China), 0.4 μg.kg⁻¹ sufentanil (EuroCept BV, Ankeveen, Netherlands), and 0.2 mg.kg⁻¹ cisatracurium (Hengrui Pharma, Lianyungang, China) were intravenously injected, and the Target-Controlled Infusion (TCI) of propofol (Fresenius, Bad Homburg, Germany) was followed to maintain a plasma target concentration of 3 μg.L⁻¹. Each patient subsequently underwent tracheal catheterization for mechanical ventilation (frequency, 11–14 times/min; tidal volume, 7–9 mL.kg⁻¹; and suction ratio, 1:2).

Regarding anesthesia maintenance, the TCI of propofol with a plasma target concentration of 2–3 μg.L⁻¹ and intravenous infusion of 0.5 μg.kg⁻¹.h⁻¹ sufentanil and 2 μg.kg⁻¹.min⁻¹ cisatracurium were performed. Each patient’s auditory evoked potential index was monitored using one A-line noninvasive anesthesia depth detector (Danmeter Ltd., Odense, Denmark) to maintain an AAI of 10–20.

After the successful completion of surgery, postoperative palinesthesia, and tracheal extubation, PCIA was induced in each patient.

Patient-controlled intravenous analgesia regimens

The patients in the COM group were administered with 150 mL of solution containing 1.0 μg.kg⁻¹ dexmedetomidine (Hengrui Pharma, Lianyungang, China) and 0.48 mg.kg⁻¹ morphine (Northeast Pharmacy, Shenyang, China); the patients in the MOR group were administered with 150 mL of solution containing 0.48 mg.kg⁻¹ morphine. The pump parameters were as follows: load, 2 mL; background infusion rate, 2 mL.h⁻¹; additional volume, 0.5 mL; locking time, 15 minutes; and maintaining postoperative pain visual analog score, ≤ 3 points. For patients with hypotension, Ramsay sedation score > 3, bradycardia, or respiratory rate < 8 beats/min, timely symptomatic treatment should be performed.

Outcomes

A 5 mL of peripheral venous blood was collected from each patient at different time points (before anesthesia induction [T0], immediately after tracheal extubation [T1], 12 hours after surgery [T2], 24 hours after surgery [T3], 48 hours after surgery [T4], 72 hours after surgery [T5], and 7 days after surgery [T6]). The contents of CD3+, CD4+, and CD8+ and Natural Killer (NK) cells in the peripheral blood were detected by FACSCalibur flow cytometry (BD, USA); the CD4+/CD8+ ratio was simultaneously calculated. The doses of morphine at T3 to T5 were recorded separately, and the adverse reactions of the two groups were compared.

Statistical analysis

Statistical analysis was performed using the Statistical Package for the Social Sciences version 21.0 statistical software. The measurement data were expressed as mean ± Standard Deviation (x̄±s) The t-test was used for the intergroup comparison. The data at different time points were compared using the repeated measurement design analysis of variance. The count data were expressed as the ratio, and the chi-squared test was used for the intergroup comparison.

Results

General conditions

A total of 118 patients (53 men and 59 women) who underwent thoracotomy in our hospital were included in this study. Their ages ranged from 41 to 60 years, and they weighted 49–65 kg, with a Body Mass Index (BMI) of 19–23 kg.m⁻². A total of 65 patients had esophageal cancer, 21 had gastric cardia cancer, and 16 had mediastinal tumor; and 16 patients previously underwent the partial resection of the lung tumor. The COM Group was composed of 57 patients (29 men and 28 women) aged 52.2 ± 6.9 years and weighing 57.2 ± 3.9 kg. The MOR group consisted of 61 patients (27 men and 34 women) aged 52.9 ± 7.4 years and weighing 57.9 ± 4.5 kg. There were no significant differences in the sex composition, age, body weight, or BMI between the two groups (Table 1).

Morphine consumption

The morphine consumption in the COM Group at T3 to T5 was significantly lower than that in the MOR Group (p<0.05) (Table 2).

Levels of CD3+, CD4+, CD8+, and natural killer cells in the peripheral blood

Compared with the contents at T0, the contents of CD3+, CD4+, CD4+/CD8+, and NK cells were significantly lower at T1 to T5 in both groups (p<0.05), while there were no significant differences in the contents of CD3+, CD4+, CD4+/CD8+, and NK cells at T6. The CD3+ level and CD4+/CD8+ ratio at T2 to T5 and the CD4+ level and NK cells at T3 to T5 in the COM group were significantly higher than those in the MOR Group (p<0.05). There were no significant differences in CD3+, CD4+, CD4+/CD8+, and NK cells between the COM Group and the MOR Group at T6 (Table 3).

Adverse reactions

The incidence of postoperative pruritus, nausea, and vomiting in the COM group was significantly lower than that of the MOR Group (p<0.05) (Table 4). Complications such as
Table 1 Comparison of general conditions of the two groups.

| Group | n   | M/F (n) | Age (years) | Weight (kg) | BMI (kg, m²) |
|-------|-----|---------|-------------|-------------|--------------|
| COM   | 57  | 29/28   | 52.2 ± 6.9  | 57.2 ± 3.9  | 21.7 ± 1.6   |
| MOR   | 61  | 27/34   | 52.9 ± 7.4  | 57.9 ± 4.5  | 21.2 ± 1.1   |

Table 2 Comparison of postoperative morphine consumption of the two groups [x ± s] mg.

| Group | n   | T3       | T4       | T5       |
|-------|-----|----------|----------|----------|
| COM   | 57  | 16.5 ± 6.7a | 35.8 ± 9.7a | 55.3 ± 8.9a |
| MOR   | 61  | 27.6 ± 9.5  | 51.9 ± 11.2 | 73.2 ± 7.6  |

Note: Compared with group MOR, a p < 0.05.

Table 3 Changes of lymphocyte subsets and NK cells in peripheral blood in different groups at different time points (x ± s).

| Index     | Group | n   | T0     | T1     | T2     | T3     | T4     | T5     | T6     |
|-----------|-------|-----|--------|--------|--------|--------|--------|--------|--------|
| CD3 (%)   | COM   | 57  | 63.1 ± 4.5 | 57.1 ± 3.7a | 54.9 ± 3.4ab | 52.7 ± 2.7ab | 57.3 ± 4.1ab | 59.7 ± 5.1ab | 62.8 ± 4.2 |
|           | MOR   | 61  | 62.8 ± 4.7 | 55.3 ± 4.1a | 52.6 ± 3.6a | 49.7 ± 4.3a | 53.6 ± 3.7a | 57.5 ± 2.4a  | 62.3 ± 4.5 |
| CD4 (%)   | COM   | 57  | 36.9 ± 4.5 | 31.7 ± 1.9a | 29.5 ± 2.2a  | 28.2 ± 2.9ab | 31.5 ± 4.3ab | 32.9 ± 5.4ab | 35.6 ± 4.0  |
|           | MOR   | 61  | 36.5 ± 4.2 | 31.9 ± 5.7a | 27.1 ± 2.9a  | 24.8 ± 3.1a  | 27.3 ± 5.2a  | 29.8 ± 3.6a  | 33.5 ± 3.7  |
| CD8 (%)   | COM   | 57  | 24.3 ± 4.4 | 23.8 ± 4.5 | 23.2 ± 4.3 | 22.9 ± 4.2 | 23.5 ± 3.9 | 24.1 ± 4.1 | 23.9 ± 4.3 |
|           | MOR   | 61  | 24.7 ± 4.6 | 24.3 ± 4.5 | 24.0 ± 4.2 | 23.9 ± 4.4 | 24.1 ± 3.9 | 23.7 ± 3.7 | 23.4 ± 4.1 |
| CD4+/CD8+ | COM   | 57  | 1.5 ± 0.3  | 1.2 ± 0.2a  | 1.2 ± 0.2ab | 1.2 ± 0.2ab | 1.3 ± 0.2ab | 1.4 ± 0.1ab | 1.5 ± 0.3  |
|           | MOR   | 61  | 1.5 ± 0.2  | 1.2 ± 0.3a  | 1.1 ± 0.2a  | 1.1 ± 0.3a  | 1.2 ± 0.1a  | 1.3 ± 0.2a  | 1.4 ± 0.2  |
| NK cells (%) | COM | 57  | 14.4 ± 1.9  | 12.1 ± 1.2a  | 11.8 ± 1.5a | 11.4 ± 1.4ab | 13.1 ± 1.3ab | 13.5 ± 1.6ab | 14.2 ± 1.7  |
|           | MOR   | 61  | 14.6 ± 2.2  | 11.9 ± 1.6a  | 11.1 ± 1.2a | 10.3 ± 1.8a | 11.6 ± 1.5a | 12.9 ± 1.4a | 14.2 ± 2.0  |

Note: Compared with T0, a p < 0.05; compared with group MOR, b p < 0.05.

Table 4 Postoperative adverse reactions in the two groups, n (%).

| Group | n   | Pruritus | Nausea | Vomiting |
|-------|-----|----------|--------|----------|
| COM   | 57  | 3 (5.3)a | 9 (15.8)a | 6 (10.5)a |
| MOR   | 61  | 13 (21.3) | 23 (37.7) | 15 (24.6) |

Note: Compared with group MOR, a p < 0.05.

hypotension, bradycardia, or excessive sedation were not observed in both groups.

Discussion

Considering the significant damage to the muscles, fascia, and other tissues, thoracotomy frequently causes more severe pain than other surgeries. Additionally, thoracotomy will affect breathing, cough, and expectoration, cause a difficulty in the discharge of respiratory secretions, and result in complications such as atelectasis, pulmonary infection, or chest infection.9

Although opioid analgesics have good analgesic effects after thoracotomy, they can also lead to adverse reactions.10 Some studies11,12 have pointed out that postoperative analgesia methods and occurrence of postoperative complications have a certain correlation. As a common postoperative analgesia method, PCAI can maintain a relatively stable blood concentration, thus avoiding the mismatch between blood concentration and analgesia, reducing the amount of analgesic medication, and subsequently obtaining better analgesic effects.13,14

In this study, all the subjects were treated with PCAI. This study referred to relevant research reports15,16 and used dexmedetomidine + morphine for postoperative analgesia, and the results showed that the morphine consumption in the COM Group at T3 to T5 was lower than that in the MOR Group. Moreover, the incidence of postoperative pruritus, nausea, and vomiting was also lower in the COM group than in the MOR Group, and complications such as hypotension, bradycardia, or excessive sedation were not observed in both groups, indicating that dexmedetomidine combined with morphine in PCAI can effectively reduce morphine consumption and postoperative complications and cause less postoperative complications, suggesting that the dosage and administration of dexmedetomidine are considered safe and effective.

The T lymphocyte subsets play an important role in maintaining the stability of the immune system.17 CD3+ is an important subset of T lymphocytes, and its number can directly reflect the level of mature T-cells in the peripheral
blood. CD4+ lymphocyte subsets are an important helper of T lymphocytes, which can help the body resist foreign microorganisms and tumor cells. CD8+ lymphocytes can inhibit the immune regulation function of the body. The stable ratio of CD4+ to CD8+ is important for maintaining the normal immune function of the body. Simultaneously, CD4+/CD8+ can also be used as an indicator of the severity and prognosis of diseases.16 The number of NK cells is important for the body’s antitumor immunity, which can directly kill tumor cells. When the in vivo cellular immune function is inhibited, the number will significantly reduce.17 The results of this study showed that compared with the contents at T0, the contents of CD3+, CD4+, CD4+/CD8+ and NK cells were lower at T1 to T5, which may be related to the oxidative stress induced by thoracotomy wounds and the immune function inhibition by morphine.20 This study showed that the CD3+ level and the CD4+/CD8+ were higher in the COM group at T2 to T5 than those in the MOR group, and the contents of CD4+ and NK cells at T3 to T5 were also higher in the COM group than those in the MOR group, indicating that dexmedetomidine can effectively reduce the inhibition of cellular immunity caused by morphine analgesia after thoracotomy.

In recent years, some studies have reported the potential benefits of dexmedetomidine for postoperative analgesia and its positive effects on immune system. Lin et al.21 suggested that the addition of dexmedetomidine to intravenous patient-controlled analgesia morphine resulted in superior analgesia, significant morphine sparing, and less morphine-induced nausea, preventing additional sedation and untoward hemodynamic changes. Cai et al.22 reported that DEX may enhance the immune function of rats with ovarian cancer by inhibiting the p38MAPK/NF-κB signaling pathway. Ma et al.23 indicated that the combined use of dexmedetomidine and flurbiprofen axetil significantly improved pain after general anesthesia thyroid surgery, reduced restlessness and postoperative cognitive dysfunction, enhanced immune function, and promoted wound repair. Dong et al.24 confirmed that dexmedetomidine can effectively reduce the release of inflammatory factors in patients who underwent the radical resection of gastric cancer, and the anti-inflammatory effect may be enhanced by downregulating the expression of NF-κB. Moreover, dexmedetomidine can also alleviate the reduction in the subgroups of CD3+ and CD4+, thereby ameliorating the impaired immune functions.

Limitations

This study is only limited to patients below 60 years-old. Whether this combination can be effective for patients over 60 years-old, as well as combining with chronic diseases or vital organ dysfunction, and whether it will have impact on the prognosis of patients still require further research and confirmation.

Conclusion

In summary, dexmedetomidine-morphine PCIA for post-thoracotomy analgesia can effectively reduce morphine consumption, reduce the occurrence of adverse reactions during analgesia and improve the cellular immune function of patients.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The funding of this study were from: National Natural Science Foundation of China (n° 81300012 and 81270074); Science and Technology Planning Project of Guangdong Province, China (n° 2016A020215025); Medical Scientific Research Foundation of Guangdong Province, China (n° A2016375); Medical Scientific Research Foundation of Health and Family Planning Commission of Shenzhen Municipality (n° 201601013 and szfz2018022); Medical Scientific Research Foundation of Shenzhen, China (n° JCYJ20160422152608675).

References

1. Yang C, Chang H, Zhang T, et al. Pre-emptive epidural analgesia improves post-operative pain and immune function in patients undergoing thoracotomy. ANZ J Surg. 2015;85:472–7.
2. Zhou Y, Huang J, Bai Y, et al. Effects of preemptive analgesia with flurbiprofen ester on lymphocytes and natural killer cells in patients undergoing esophagectomy: A randomized controlled pilot study. Thorac Cancer. 2017;8:649–54.
3. Carregaro AB, Freitas GC, Lopes C, et al. Evaluation of analgesic and physiologic effects of epidural morphine administered at a thoracic or lumbar level in dogs undergoing thoracotomy. Vet Anaesth Analg. 2014;41:205–11.
4. Murphy JD, Paskaradevan J, Eisler LL, et al. Analgesic efficacy of continuous intravenous magnesium infusion as an adjuvant to morphine for postoperative analgesia: a systematic review and meta-analysis. Middle East J Anaesthesiol. 2013;22:11–20.
5. Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013;110:915–25.
6. Bajwa SJ, Kaur J, Singh A, et al. Attenuation of pressor response and dose sparing of opioids and anaesthetics with pre-operative dexmedetomidine. Indian J Anaesth. 2012;56:123–8.
7. Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116:1312–22.
8. Khalil MA, Abdel Azeem MS. The impact of dexmedetomidine infusion in sparing morphine consumption in off-pump coronary artery bypass grafting. Semin Cardiothorac Vasc Anesth. 2013;17:66–71.
9. Reichert M, Posentrup B, Becker A, et al. Thoracotomy versus video-assisted thoracoscopic surgery (VATS) in stage III empyema-an analysis of 217 consecutive patients. Surg Endosc. 2018;32:2664–75.
10. Hetmann F, Kongsgaard UE, Sandvik L, et al. Post-thoracotomy pain syndrome and sensory disturbances following thoracotomy at 6- and 12-month follow-ups. J Pain Res. 2017;10:663–8.
11. Sharma R, Gupta R, Choudhary R, et al. Postoperative Analgesia with Intravenous Paracetamol and Dexmedetomidine in Laparoscopic Cholecystectomy Surgeries: A Prospective Randomized Comparative Study. Int J Appl Basic Med Res. 2017;7:218–22.
12. Li Y, Geng J, Wen L, et al. Postoperative analgesia with ropivacaine and dexmedetomidine for ultrasound-guided fascia iliaca compartment block after arthroscopic knee surgery. Saudi J Anaesth. 2019;13:100–5.

13. Wang C, Li L, Shen B, et al. A multicenter randomized double-blind prospective study of the postoperative patient controlled intravenous analgesia effects of dezocine in elderly patients. Int J Clin Exp Med. 2014;7:530–9.

14. Dong CS, Zhang J, Lu Q, et al. Effect of Dexmedetomidine combined with sufentanil for post-thoracotomy intravenous analgesia: a randomized, controlled clinical study. BMC Anesthesiol. 2017;17:33.

15. Bengisu ZK, Ekmekci P, Akan B, et al. The effect of adding dexmedetomidine to levobupivacaine for interscalene block for postoperative pain management after arthroscopic shoulder surgery. Clin J Pain. 2014;30:1057–61.

16. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine-based therapy after cardiac surgery: a randomized controlled trial (Dexmedetomidine Compared to Morphine-DEXCOM Study). Anesthesiology. 2009;111:1075–84.

17. Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014;15:1104–15.

18. Fujimoto N, Kito K, Yoshida T, Tanaka T. Primary cutaneous CD4/CD8-/- TCRalphabeta T-cell lymphoma. Acta Derm Venereol. 2015;95:106–7.

19. Melero I, Rouzaut A, Motz GT, et al. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4:522–6.

20. Mizota T, Tsujikawa H, Shoda T, et al. Dual modulation of the T-cell receptor-activated signal transduction pathway by morphine in human T lymphocytes. J Anesth. 2013;27:80–7.

21. Lin TF, Yeh YC, Lin TFS, et al. Effect of combining dexmedetomidine and morphine for intravenous patient-controlled analgesia. Br J Anaesth. 2009;102:117–22.

22. Cai QH, Tang Y, Fan SH, et al. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-kB signaling pathway. Biomed Pharmacother. 2017;95:1830–7.

23. Ma XD, Li BP, Wang DL, et al. Postoperative benefits of dexmedetomidine combined with flurbiprofen axetil after thyroid surgery. Exp Ther Med. 2017;14:2148–52.

24. Dong W, Chen MH, Yang YH, et al. The effect of dexmedetomidine on expressions of inflammatory factors in patients with radical resection of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:3510–5.